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Abstract
Background: The impact of smoking on TNF inhibition (TNFi) therapy is unclear. We examined the effect of
smoking on all-cause and cause-specific TNFi discontinuation in axial spondyloarthritis (axSpA).
Methods: We used longitudinal data from the British Society for Rheumatology Biologics Register for Ankylosing
Spondylitis (BSRBR-AS). Patients fulfilling the ASAS criteria for axSpA, who started their first TNFi, were eligible for
analysis. Inverse-probability weights were used to balance differences in baseline disease severity and other
confounders. We used marginal structural Cox proportional hazard models to estimate hazard ratios (HR) for TNFi
discontinuation according to smoking status. In analyses of cause-specific discontinuation, competing risk events
were considered as censoring, using inverse-probability weights.
Results: A total of 758 participants were included in the analysis (66% male, mean age 45 years), providing 954
patient-years of follow-up. TNFi was discontinued in 174 (23%) patients, among whom 26% stopped due to
infections, 20% due to other adverse events and 44% due to inefficacy or other reasons. Thirty-four percent were
current smokers and 30% ex-smokers. Compared to never smokers, current smokers’ risk of TNFi discontinuation
was HR 0.79 (95%CI 0.53 to 1.20) and ex-smokers HR 0.68 (95%CI 0.45 to 1.04). Our data did not show evidence that
current smoking influenced discontinuation due to infections (HR 0.79, 95%CI 0.40 to 1.54), other adverse events
(HR 0.86, 95%CI 0.41 to 1.78) or inefficacy/other causes (HR 1.44, 95%CI 0.86 to 2.41).
Conclusion: Baseline smoking status did not impact TNFi discontinuation in this UK cohort of axSpA participants.
Keywords: Axial spondyloarthritis, Ankylosing spondylitis, TNF inhibitor, Biologic DMARDs, Persistence, Effectiveness,
Response, Discontinuation, Marginal structural model
Background
The aetiological and prognostic roles of cigarette smoking
in rheumatoid arthritis are well-established, but its role in
axial spondyloarthritis (axSpA) remains unclear. Clinically
meaningful differences in response to TNF inhibitors
(TNFi) have not been demonstrated in axSpA when con-
tinuous outcomes are used, such as the Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) [1–3]. In
contrast, analyses using binary response variables, such as
BASDAI50 (50% reduction), found current smokers to
have significantly lower odds of TNFi response compared
to never smokers [1, 4]. Since all causes of discontinuation
are often counted as non-response, increased drug discon-
tinuation in smokers may explain this discrepancy.
One prior study reporting increased risk of treatment
discontinuation in smokers did not adjust for socioeco-
nomic status, comorbidities or baseline disease severity
[4]. Since these are potential confounders or known pre-
dictors of TNFi discontinuation [5], limited conclusions
can be drawn about the independent relationship be-
tween smoking and TNFi discontinuation.
Patients stop TNFi for several reasons, including inef-
ficacy, adverse events or other reasons, such as patients’
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social circumstances. Infections are adverse events of
special interest since smoking is a substantial risk factor
for bacterial and viral infections [6]. Whether the effect
of smoking differs according to each cause of TNFi dis-
continuation is not known. Once treatment is stopped
for one reason (e.g. adverse events), the individual can
no longer be at risk of other causes of discontinuation
(e.g. inefficacy) in that treatment episode. When an
event either precludes observation of the outcome of
interest or modifies its probability, “competing risks” is
present [7]. When competing risks are not rare, i.e. > 5%
of the population, traditional survival analyses should
not be used and additional methodological consider-
ations are needed to appropriately understand a poten-
tial association between smoking and TNFi
discontinuation.
The aim of the current analyses was to examine the
impact of smoking on all-cause and cause-specific TNFi
discontinuation in patients with axSpA, using marginal
structural models to address the above methodological
issues.
Methods
Study design and population
We used data from the British Society for Rheumatology
Biologics Register for Ankylosing Spondylitis (BSRBR-
AS), a UK-wide prospective cohort study of patients ful-
filling the Assessment of SpondyloArthritis international
Society (ASAS) criteria for axSpA [8]. The current ana-
lysis focused on new users of TNFi (Humira, Enbrel/
Benepali, Cimzia and Simponi) from December 2012 to
June 2017. Patients were assessed at baseline, 3, 6 and
12months and annually thereafter, with additional
follow-ups permitted in the interim. TNFi start and stop
dates were ascertained from their medical notes. Partici-
pants who completed a valid baseline questionnaire
(within 1 year before and 7 days after starting TNFi) and
recorded smoking status were eligible for analysis.
Exposure and outcomes
Self-reported smoking status at baseline (current, ex- or
never) was used to define the exposure. The outcomes
of interest were time to all-cause and cause-specific
TNFi discontinuation. Reasons for stopping were cate-
gorised in the BSRBR-AS as adverse events, inefficacy,
symptom in remission, or other, with accompanying
free-text to further elaborate. Each entry was manually
reviewed and, where necessary, re-categorised. To allow
comparison with existing studies, and so that each spe-
cific cause has sufficient events with which to perform
the analyses, we grouped causes as (1) infection-related
adverse events, (2) all other adverse events, and (3) inef-
ficacy or other reasons (e.g. patient choice and social cir-
cumstances). The censoring date was defined as the last
study visit or, if no data existed past the baseline visit, as
3 months (the minimum per protocol follow-up
interval).
Covariates
The following covariates were recorded at baseline and
chosen a priori for their possible associations with TNFi
discontinuation based on prior literature [5]: age, gender,
symptom duration, education, elevated baseline CRP (above
upper normal limit), classification as ankylosing spondylitis
(modified New York criteria), social deprivation (quintiles)
[9], alcohol use (current, previous, never), comorbidity
(categorised as 0, 1 or ≥ 2 from a list of 13 conditions [8]),
body mass index (BMI), TNFi agent and year of TNFi initi-
ation. Patient-reported variables were measured at each
follow-up; those known to be associated with TNFi discon-
tinuation include BASDAI, spinal pain, functional impair-
ment (BASFI) and fatigue (Chalder Fatigue Scale). Since
these variables capture more than just disease activity, we
refer to them collectively as “disease severity” throughout
the text.
Statistical analysis
Baseline participant characteristics were summarised by
smoking status. Unadjusted comparison of time to all-
cause discontinuation according to smoking status was
made using Kaplan-Meier estimators.
Prior studies considered each cause of TNFi discon-
tinuation as censoring [10]. In traditional survival ana-
lysis, observation time for each subject is censored when
they leave the study or at the end of follow-up. Further-
more, a key assumption of Cox models is that censored
patients should be representative of remaining individ-
uals at that time point (i.e., censoring is random).
Patients who discontinue treatment are not representa-
tive of those who continue; therefore, Cox models can-
not be used.
Marginal structural models use inverse-probability
weights to account for confounders rather than adjusting
for them in conventional outcome regression [11]. This
approach is more flexible, allowing us to account for
baseline imbalance in characteristics between smoking
status, time-varying disease activity, and competing risk
events within one model. For all following analyses,
differences in baseline covariates between smoking cat-
egories were balanced using inverse probability of “treat-
ment” weights (IPTW) [11] to allow unconfounded
descriptive comparisons [12]. Causal inference is not
straightforward regarding the effect of baseline smoking
status on TNFi discontinuation, since we cannot ran-
domly assign an individual to “having smoked for 20
years” at the onset of a hypothetical trial. IPTW provides
an approach to estimate causal effects under theoretical
ideal conditions and may be advantageous over
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regression adjustment (see Additional file 1). We derived
IPTW using predicted values from a multinomial logistic
regression model, using baseline smoking status as the
dependent variable and all baseline covariates specified
above as independent variables.
We applied baseline time-invariant inverse probability
of censoring weights (IPCW) to account for participants
excluded from the sample eligible for analysis, such that
baseline characteristics of the analysis set resembled the
eligible TNFi exposed cohort. These IPCWs were con-
structed in the same manner as IPTWs, with inclusion/
exclusion status as the dependent variable.
We used marginal structural Cox proportional hazards
models to estimate hazard ratios of TNFi discontinu-
ation according to baseline smoking status [11, 13].
Parameters were estimated using weighted pooled logis-
tic models that are equivalent to Cox models when using
discrete time [14] and allow the use of subject-specific
time-varying weights. Time was split into integer
months [13].
Censoring becomes non-random when competing risk
events are specified as censoring. We therefore calcu-
lated time-varying IPCWs, such that censoring becomes
random at each time point with respect to baseline char-
acteristics and history of disease activity [15]. For
analysis of each specific cause of TNFi discontinuation
(e.g. infection), the other competing risk events (e.g.
other reasons) were treated as censoring events.
Weighted pooled logistic models included only the
outcome, exposure (smoking status) and time, which
was included in all models as restricted cubic splines
[13]. All weights were “stabilised” to have a mean of 1,
allowing the overall sample size to remain unchanged
[16]. Further details of the methods are given in [13].
Multiple imputation was used for missing covariates.
Analyses were conducted using Stata version 13.
Results
Among a total of 2420 participants in the BSRBR-AS,
840 commenced their first TNFi within the study period
and had smoking status recorded at baseline. Eighty-two
participants were excluded because they did not have a
valid baseline assessment. Excluded participants had
longer symptom duration, more frequently met classifi-
cation criteria for AS and were more frequently male
(full comparison in Additional file 1: Table S1). Seven
hundred fifty-eight participants were included in the
analysis set, providing 954 patient-years of follow-up.
The median follow-up time was 1.0 year (inter-quartile
range 0.4 to 2.0 years).
TNFi was discontinued in 174 (23%) patients. The me-
dian time to discontinuation was 6 months (inter-quar-
tile range 3 to 11). Among those who stopped TNFi,
26% stopped due to infections, 20% due to other adverse
events and 44% due to inefficacy or other reasons, with
no differences according to smoking status. Recoding of
discontinuation causes is shown in Additional file 1:
Table S2.
Baseline characteristics of the analysis cohort are
shown in Table 1. Thirty-four percent of patients were
current smokers, 30% ex-smokers and 36% never
smokers. Current smokers were younger, were more fre-
quently male and showed trends for having higher
deprivation and lower educational attainment. Current
smokers also more frequently had elevated CRP. The
three groups did not differ in age of symptom onset.
Current smokers reported worse baseline disease activity
and functional impairment. Covariate imbalance was
negligible (standardised mean differences < 0.1) after
weighting for IPTW (Additional file 1: Figure S1).
All-cause TNFi discontinuation
Using marginal structural models, hazard ratios for all-
cause TNFi discontinuation did not significantly differ in
current (HR 0.79; 95%CI 0.53 to 1.20) or ex-smokers
(HR 0.68; 95%CI 0.45 to 1.04), compared to never
smokers. Unadjusted Kaplan-Meier estimators are
shown in Additional file 1: Figure S2.
Cause-specific TNFi discontinuation
Hazard ratios for each of the three causes of TNFi dis-
continuation according to smoking status are shown in
Table 2. Our data did not provide evidence that current
or previous smoking affected discontinuation due to in-
fection, other adverse events or inefficacy/other reasons.
Discussion
In this large UK cohort of axSpA participants, smoking
was associated with significantly worse disease severity
at initiation of TNFi therapy. However, TNFi discontinu-
ation was not associated with baseline smoking status.
Our results also did not provide evidence that smoking
affected discontinuation due to infection-related or other
adverse events. The results did suggest that current
smokers may have higher risk of discontinuation due to
inefficacy or other reasons.
The main strengths of this study are the quality of data
and use of rigorous analyses. The BSRBR-AS cohort is
representative of UK clinical practice, and its rich data-
set allowed us to adjust for a large number of con-
founders. The use of inverse-probability weights allowed
us to conduct improved time-to-event analysis for each
cause of TNFi discontinuation (competing risk events),
while accounting for baseline differences between expos-
ure groups and time-varying disease activity within one
model.
Our data did have some important limitations. While
smoking has been recorded in detail, information on
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time since smoking cessation was not recorded. The
proportion stopping due to adverse events was higher,
while inefficacy was much lower, than reported else-
where; nevertheless, the proportion of TNFi discontinu-
ation was in keeping with existing literature [10]. In
clinical practice, there is often an overlap between how
inefficacy and adverse events are defined and reported.
For instance, inflammation in previously unaffected
peripheral joints may be reported as an adverse event,
when it would more appropriately reflect lack of disease
control and efficacy; therapy is more likely to continue
in the face of mild adverse events if they are highly ef-
fective for symptom control. Before 2016—that is, the
majority of this study period—the UK National Institute
for Health and Care Excellence stipulated that patients
who did not demonstrate initial or maintained response
Table 1 Baseline characteristics and causes of discontinuation among 758 participants, according to smoking status
Never smoker
(n = 224)
Ex-smoker
(n = 177)
Current smoker
(n = 197)
P value
Age, mean (SD) years 43.3 (14.5) 50.0 (12.8) 42.2 (11.8) < 0.001
Male 167 (62%) 149 (65%) 188 (73%) 0.012
Meets mNY criteria for AS 164 (61%) 154 (67%) 162 (63%) 0.360
HLA-B27 positive+ 143 (70%) 125 (76%) 148 (80%) 0.088
Elevated CRP* 150 (57%) 129 (59%) 161 (67%) 0.043
Age at symptom onset, median (IQR) years 26.0 (20.0 to 33.0) 26.0 (22.0 to 34.0) 26.0 (21.0 to 33.0) 0.350
Symptom duration, median (IQR) years 12.4 (4.2 to 26.0) 20.7 (10.3 to 32.5) 12.3 (5.5 to 22.9) < 0.001
BMI, mean (SD) 27.9 (6.2) 28.8 (5.1) 27.4 (5.8) 0.060
Quintiles of Index of Multiple Deprivation 1, most deprived 39 (14%) 33 (14%) 85 (33%) < 0.001**
2 54 (20%) 30 (13%) 43 (17%)
3 52 (19%) 53 (23%) 51 (20%)
4 68 (25%) 56 (24%) 47 (18%)
5, most affluent 58 (21%) 59 (26%) 30 (12%)
Highest level of education Secondary school 72 (27%) 75 (33%) 114 (45%) < 0.001
Apprenticeship 18 (7%) 24 (10%) 29 (12%)
Further education college 83 (31%) 81 (35%) 71 (28%)
University degree 70 (26%) 38 (17%) 29 (12%)
Further degree 26 (10%) 11 (5%) 9 (4%)
Alcohol status Never 31 (11%) 14 (6%) 30 (12%) < 0.001
Ex 34 (13%) 43 (19%) 68 (27%)
Current 205 (76%) 174 (75%) 158 (62%)
Number of comorbidities 0 163 (61%) 117 (51%) 137 (54%) 0.051**
1 77 (29%) 68 (30%) 78 (30%)
≥ 2 28 (10%) 43 (19%) 41 (16%)
BASDAI, median (IQR) 6.3 (4.8 to 7.4) 6.6 (5.2 to 7.9) 7.1 (5.5 to 7.9) 0.001
Spinal pain, median (IQR) 6.0 (4.0 to 8.0) 7.0 (5.0 to 8.0) 7.0 (5.0 to 8.0) 0.002
BASFI, median (IQR) 5.7 (3.7 to 7.6) 6.6 (4.8 to 8.3) 7.0 (5.1 to 8.6) < 0.001
Chalder Fatigue Scale, median (IQR) 17.0 (14.0 to 21.0) 17.0 (13.0 to 21.0) 18.0 (13.0 to 22.0) 0.340
Remained on treatment 62 (23%) 49 (21%) 63 (25%) 0.670
Stopped treatment Infection 20 (32%) 18 (37%) 15 (24%) 0.176
Other adverse events 17 (27%) 15 (31%) 13 (21%)
Inefficacy or other reasons 25 (40%) 16 (33%) 33 (56%)
Data presented as mean (standard deviation), median (interquartile range), number (percentage). Comparisons used t-test for continuous variables, chi-square test
for categorical variables. Italicized text highlights significant differences. Examples of “other reasons” included patient choice and social circumstances
+HLA-B27 status available for 448 participants
*Above upper normal limit
**Non-parametric test for trend across ordered groups
SD standard deviation, IQR interquartile range, mNY modified New York criteria for Ankylosing Spondylitis, BMI body mass index, BASDAI Bath AS Disease Activity
Index, BASFI Bath AS Functional Index
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to treatment would not be funded to use a second TNFi
[17, 18]. However, switching to a second TNFi was
allowed if discontinuation was due to the development
of a treatment-related adverse event. This may have in-
fluenced labelling of discontinuation as adverse events
or other reasons. These errors would not affect analysis
of all-cause discontinuation or discontinuation due to
infection-related adverse events. It would have been in-
teresting to examine the effect of changing smoking sta-
tus at the individual level, but the number of such
participants was too small to permit analysis. It is pos-
sible that TNFi stop dates in medical notes may be influ-
enced by recall error; however, there is no evidence to
suggest that such error differs according to smoking sta-
tus, so we do not believe this will have introduced a bias.
Lastly, the BSRBR-AS did not record pack-years to
examine the effect of cumulative exposure. A significant
effect is unlikely since none was found for ever vs never
smokers.
There has been only one previous study of TNFi dis-
continuation and smoking in ankylosing spondylitis.
Glintborg et al. reported increased risk of all-cause TNFi
discontinuation in current and ex-smokers [4]. Com-
pared to their study, our follow-up period was short. It
is possible that differences in treatment persistence only
becomes apparent with longer follow-up, although sep-
aration in Kaplan-Meier curves was clear by 2 years in
their study [4]. Importantly, Glintborg et al. did not
adjust for baseline differences in disease severity and
BMI from their primary analysis, on account of the fact
that these variables are potential mediators. Without
adjusting for these known predictors of TNFi persistence
[5, 19], it is difficult to attribute a causal effect of smok-
ing on TNFi discontinuation. In DANBIO studies of
psoriatic arthritis, significant differences in TNFi persist-
ence were reported when analyses did not adjust for
BMI and baseline disease severity [10], while analysis
using essentially the same cohort but additionally adjust-
ing for these covariates did not find such difference [20]
(see Additional file 1: Table S4 for comparison).
Our negative results may have other explanations. The
prevalence of current smoking was higher in DANBIO
(43%) than in the BSRBR-AS (29%). Furthermore, we did
not find smoking to be associated with age of symptom
onset as previously reported [21]. It is possible that there
are differences between the study cohorts. Our results are
consistent with a growing body of evidence that smoking
status does not independently impact TNFi treatment. In
a study of obesity and TNFi response in axSpA, current
smoking (as a covariate in their multivariable Cox regres-
sion model) was not associated with TNFi discontinuation
(HR 0.92; 95%CI 0.66 to 1.28) [19]. Smoking status at
TNFi initiation also did not affect treatment response in
several studies [2, 19, 22–25], including a recent analysis
of the BSRBR-AS [3]. These results should persuade clini-
cians to dispel any subconscious bias that smokers may
not benefit as much from TNFi treatment.
We cannot exclude the possibility that smoking in
early stages of the disease causes more severe disease
observed at TNFi initiation. It is unknown whether
smoking cessation improves disease severity irrespective
of treatment. Smoking cessation remains a priority since
patients with rheumatic diseases have high burdens of
cardiovascular disease and the combined impact of TNFi
and smoking on malignancy risk is unknown. Further-
more, smoking may be associated with greater radio-
graphic progression [26].
Conclusion
Smokers commencing TNFi were no more likely to discon-
tinue treatment than never smokers in this large UK cohort
of axSpA participants. To better estimate causal effects of
smoking exposure, future studies would benefit from re-
cording more detailed smoking history, and exploring
cause-specific treatment discontinuation in larger cohorts
with clearer recording of reasons for discontinuation.
Additional file
Additional file 1: Table S1. Characteristics of the 840 patients exposed
to TNFi and had smoking status, according to whether they were eligible
for longitudinal analysis or were excluded. Table S2. Recoding mis-labelled
discontinuation causes in the registry data. Table S3. Descriptions of stabi-
lised inverse-probability weights used in analyses. Table S4. Comparing
results from studies of TNFi persistence according to covariates used in their
analysis models, particularly whether they have accounted for baseline
disease severity. Figure S1. Standardised mean differences (SMD) for base-
line variables before and after inverse-propensity weighting. Figure S2.
Kaplan-Meier curves comparing all-cause discontinuation between smoking
status. (DOCX 141 kb)
Table 2 All-cause and cause-specific treatment discontinuation according to baseline smoking status, after balancing differences in
baseline covariates and accounting for those excluded from the analysis
Never smoker Ex-smoker Current smoker
All-cause Reference 0.68 (0.45 to 1.04) 0.79 (0.53 to 1.20)
Infection-related adverse events Reference 1.03 (0.55 to 1.96) 0.79 (0.40 to 1.54)
Other adverse events Reference 1.02 (0.50 to 2.07) 0.86 (0.41 to 1.78)
Inefficacy and other reasons Reference 0.73 (0.39 to 1.37) 1.44 (0.86 to 2.41)
Results shown as hazard ratios (95% confidence interval). Examples of “other reasons” included patient choice and social circumstances
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